The purpose of this study is to test whether patients with breast cancer who are being treated with non-anthracycline trastuzumab therapy can safely be monitored for heart related side effects less often than usual.
Age >/= 18 years Newly diagnosed histologically confirmed primary invasive breast carcinoma (Stage I-IV) Pathologically confirmed HER2-positive breast cancer Planned to receive trastuzumab-based therapy for a minimum of 12 months, or started trastuzumab-based therapy within the last weeks with a planned duration of at least 12 months. Normal LV systolic function (EF greater than or equal to the institutional lower limit of normal) William and able to comply with the requirements of the protocol
Exclusion Criteria:
Planned to receive an anthracycline-based regimen Prior history of treatment with anthracycline chemotherapy History of cardiovascular including cardiomyopathy, heart failure, or any other clinically significant cardiovascular disease (as determined by the investigator) Uncontrolled hypertension, defined as systolic blood pressure >/= 160 mmHg and/or diastolic blood pressure >/= 90 mmHg (as determined by the investigator)
